Clinical trial: Measurement Properties of the Walking Adaptability Ladder Test and Foot Tap Test in People With Multiple Sclerosis With Mild Disability

https://clinicaltrials.gov/study/NCT07505355?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20349

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

Clinical trial: An Open-label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis

https://clinicaltrials.gov/study/NCT07503340?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20338

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

Clinical trial: A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector Device Versus Syringe in Patients With Multiple Sclerosis

https://clinicaltrials.gov/study/NCT07503873?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20339

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

Superpower Aims for FDA Approval of Peptides

Superpower Medical will test peptides like epitalon and BPC-157 in new trials. They hope to get FDA approval for these wellness compounds.

#PeptideTherapy, #FDA, #ClinicalTrials, #Epitalon, #BPC157

https://newsletter.tf/superpower-medical-fda-peptide-trials/

Superpower Medical is starting trials for peptides, aiming for FDA approval. This could make popular wellness compounds more official.

#PeptideTherapy, #FDA, #ClinicalTrials, #Epitalon, #BPC157
https://newsletter.tf/superpower-medical-fda-peptide-trials/

Clinical trial: Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?

https://clinicaltrials.gov/study/NCT07504120?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20340

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

The article reports on a phase IIa trial showing that a single intravenous dose of DMT, combined with structured psychological support, can rapidly reduce depressive symptoms and sustain improvement for up to three months in adults with major depressive disorder.

This finding is of interest to psychology readers because it highlights how brief psychedelic experiences, when paired with targeted therapy, may shift mood symptoms quickly and emphasize the role of therapeutic context in treatment outcomes.

Article Title: Short-acting psychedelic DMT shows promise as a rapid treatment for major depressive disorder

Link to PsyPost Article: https://www.psypost dot org/short-acting-psychedelic-dmt-shows-promise-as-a-rapid-treatment-for-major-depressive-disorder/

Copy and paste broken link above into your browser and replace "dot" with "." for link to work. We have to do it this way to avoid displaying copyrighted images.

#psychedelics #depression #psychotherapy #DMT #clinicaltrials

Clinical trial: Clinical Efficacy of a teLerehabilItation Protocol, for the Improvement of Balance in Degenerative neurOlogical Diseases

https://clinicaltrials.gov/study/NCT07502066?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20326

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

Clinical trial: A Randomized Controlled Trial of a Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis: The Effect of Dietary Interventions on Clinical Findings, Plasma Histamine, and Oxidative Stress

https://clinicaltrials.gov/study/NCT07501520?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20327

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology

Clinical trial: Skeletal Muscle Aging and Responsiveness in Aged People With MS

https://clinicaltrials.gov/study/NCT07500727?utm_source=fediverse&utm_medium=mastodon&utm_content=trial_20328

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology